Unknown

Dataset Information

0

Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.

ABSTRACT: Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases. We report a series of compounds based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity. Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminopyridine hydrogen bondings with Ser538 and Asp539, and by hydrophobic interaction of trifluoropyridine in the back pocket. These interactions are evident in the X-ray crystal structure of the lead compounds 1 and 3 in the complex with the BTK enzyme. Our lead compounds show desirable PK profiles and efficacy in the preclinical rat collagen induced arthritis model.

SUBMITTER: Liu J 

PROVIDER: S-EPMC4753550 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Discovery of 8-Amino-imidazo[1,5-a]pyrazines as Reversible BTK Inhibitors for the Treatment of Rheumatoid Arthritis.

Liu Jian J   Guiadeen Deodial D   Krikorian Arto A   Gao Xiaolei X   Wang James J   Boga Sobhana Babu SB   Alhassan Abdul-Basit AB   Yu Younong Y   Vaccaro Henry H   Liu Shilan S   Yang Chundao C   Wu Hao H   Cooper Alan A   de Man Jos J   Kaptein Allard A   Maloney Kevin K   Hornak Viktor V   Gao Ying-Duo YD   Fischmann Thierry O TO   Raaijmakers Hans H   Vu-Pham Diep D   Presland Jeremy J   Mansueto My M   Xu Zangwei Z   Leccese Erica E   Zhang-Hoover Jie J   Knemeyer Ian I   Garlisi Charles G CG   Bays Nathan N   Stivers Peter P   Brandish Philip E PE   Hicks Alexandra A   Kim Ronald R   Kozlowski Joseph A JA  

ACS medicinal chemistry letters 20151219 2

Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition and for the treatment of B cell related diseases. We report a series of compounds based on 8-amino-imidazo[1,5-a]pyrazine that are potent reversible BTK inhibitors with excellent kinase selectivity. Selectivity is achieved through specific interactions of the ligand with the kinase hinge and driven by aminop  ...[more]

Similar Datasets

Unknown Discovery of Imidazo[1,2-a]pyrazines and Pyrazolo[1,5-c]pyrimidines as TARP γ-8 Selective AMPAR Negative Modulators.
| S-EPMC6421542 | biostudies-literature
Unknown 2- and 3-substituted imidazo[1,2-a]pyrazines as inhibitors of bacterial type IV secretion.
| S-EPMC4339681 | biostudies-literature
Unknown Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development.
| S-EPMC9879287 | biostudies-literature
Unknown Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors.
| S-EPMC4291715 | biostudies-literature
Unknown Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function.
| S-EPMC9175945 | biostudies-literature
Unknown Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
| S-EPMC4468400 | biostudies-literature
Unknown Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.
| S-EPMC5428509 | biostudies-literature
Unknown Discovery of potent and reversible monoacylglycerol lipase inhibitors.
| S-EPMC3034734 | biostudies-literature
Unknown Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.
| S-EPMC5150666 | biostudies-literature
Unknown Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors.
| S-EPMC6154558 | biostudies-literature